GSK (GSK) and Eli Lilly (LLY) are the latest drugmakers to reveal plans to build new manufacturing plants and other operations in the U.S., a move that aims to partly mitigate the threat of tariffs, Peter Loftus of The Wall Street Journal reports. According to the Journal’s tally of company announcements, more than a dozen drugmakers this year have pledged to spend over $350B in the U.S. by the end of the decade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Trump’s UK Visit Prompts GSK to Commit $30B in U.S. Investment
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots
- GSK’s New Study on Bepirovirsen: A Potential Game-Changer for Hepatitis B Treatment?
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads
- Omnicom, WPP under pressure after Trump moves to regulate pharma ads